Dusquetide

Drug Profile

Dusquetide

Alternative Names: IDR-1; Innate defense regulator-1; SGX-94; SGX-942; SGX-943

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator University of British Columbia
  • Developer Soligenix; The Childrens Hospital of Philadelphia; University of British Columbia
  • Class Anti-inflammatories; Antibacterials; Peptides; Proteins
  • Mechanism of Action Immunomodulators; SQSTM1-protein-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lymphoproliferative disorders; Acute radiation syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Stomatitis
  • Preclinical Acute radiation syndrome; Lymphoproliferative disorders; Melioidosis
  • No development reported Bacterial infections

Most Recent Events

  • 05 Jan 2017 Soligenix receives positive Scientific Advice from the EMA for dusquetide in Stomatitis
  • 12 Dec 2016 Dusquetide receives Promising Innovative Medicine designation for Stomatitis in the United Kingdom
  • 08 Dec 2016 Soligenix receives grant from National Institute of Allergy and Infectious Diseases (NIAID) and Biomedical Advanced Research and Development Authority (BARDA) for dusquetide development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top